Dr. Gainor on Potential With BLU-667 in RET+ NSCLC

Justin Gainor, MD
Published: Wednesday, Jun 19, 2019



Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses clinical activity and tolerability of BLU-667 in patients with advanced RET fusion–positive non–small cell lung cancer (NSCLC).

BLU-667 is a highly potent and selective RET inhibitor targeting oncogenic RET alterations, including those that confer resistance to multikinase inhibitors. There are no currently FDA-approved RET inhibitors to date. Patients enrolled in the study had RET-altered advanced solid tumors and received 30 mg to 600 mg of oral BLU-667 daily. The first part of the ARROW study determined 400 mg of BLU-667 daily as the recommended dose.

The second part of the ARROW study sought to identify the overall response rate (ORR) and safety of BLU-667. The study enrolled 120 patients, 91 of them having completed prior platinum-based chemotherapy. Of all patients, 84% had received prior therapy; 77% had chemotherapy, 39% had a PD-1/PD-L1 inhibitor, 34% had the combination of chemotherapy and a checkpoint inhibitor, and 18% received a multikinase inhibitor.

Treatment-related toxicity was generally low-grade, with some adverse events including constipation (17%; grade ≥3, 2%), neutropenia (26; grade ≥3, 13%), aminotransferase increase (20%; grade ≥3, 2%), fatigue (13%; grade ≥3, 3%), and hypertension (13%; grade ≥3, 10%).

The preliminary efficacy of BLU-667 was evaluated in 48 patients. Results showed that the ORR was 58% and the disease control rate (DCR) was 96%. Of those 48 patients, 35 received prior platinum-based chemotherapy. In that subgroup, the ORR was 60% and the DCR was 100%.

These data support the expansion of the ARROW trial in treatment-naïve NSCLC patients and continued enrollment of other RET-altered solid tumor groups.
SELECTED
LANGUAGE


Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses clinical activity and tolerability of BLU-667 in patients with advanced RET fusion–positive non–small cell lung cancer (NSCLC).

BLU-667 is a highly potent and selective RET inhibitor targeting oncogenic RET alterations, including those that confer resistance to multikinase inhibitors. There are no currently FDA-approved RET inhibitors to date. Patients enrolled in the study had RET-altered advanced solid tumors and received 30 mg to 600 mg of oral BLU-667 daily. The first part of the ARROW study determined 400 mg of BLU-667 daily as the recommended dose.

The second part of the ARROW study sought to identify the overall response rate (ORR) and safety of BLU-667. The study enrolled 120 patients, 91 of them having completed prior platinum-based chemotherapy. Of all patients, 84% had received prior therapy; 77% had chemotherapy, 39% had a PD-1/PD-L1 inhibitor, 34% had the combination of chemotherapy and a checkpoint inhibitor, and 18% received a multikinase inhibitor.

Treatment-related toxicity was generally low-grade, with some adverse events including constipation (17%; grade ≥3, 2%), neutropenia (26; grade ≥3, 13%), aminotransferase increase (20%; grade ≥3, 2%), fatigue (13%; grade ≥3, 3%), and hypertension (13%; grade ≥3, 10%).

The preliminary efficacy of BLU-667 was evaluated in 48 patients. Results showed that the ORR was 58% and the disease control rate (DCR) was 96%. Of those 48 patients, 35 received prior platinum-based chemotherapy. In that subgroup, the ORR was 60% and the DCR was 100%.

These data support the expansion of the ARROW trial in treatment-naïve NSCLC patients and continued enrollment of other RET-altered solid tumor groups.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x